Agnes Veyradier

Summary

Country: France

Publications

  1. doi request reprint [ADAMTS13, von Willebrand factor specific cleaving protease]
    Agnes Veyradier
    Service d Hematologie Biologique, Hopital Antoine Beclere, Groupe Hospitalier Paris Sud, AP HP, 157, rue de la Porte de Trivaux, 92140 Clamart, France
    Med Sci (Paris) 27:1097-105. 2011
  2. doi request reprint Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis
    A Veyradier
    Service d Hematologie Biologique, Hopital Antoine Beclere, Clamart Cedex, France
    Haemophilia 17:944-51. 2011
  3. doi request reprint Von Willebrand factor and ADAMTS13: a candidate couple for preeclampsia pathophysiology
    Alain Stepanian
    AP HP Hôpital Antoine Béclère, Service d Hematologie Biologique, 157 rue de la Porte de Trivaux, 92141 Clamart Cedex, France
    Arterioscler Thromb Vasc Biol 31:1703-9. 2011
  4. ncbi request reprint Thrombotic thrombocytopenic purpura associated with von Willebrand factor-cleaving protease (ADAMTS13) deficiency in children
    Chantal Loirat
    Service de Nephrologie Pediatrique, Hopital Robert Debre, Paris, France
    Semin Thromb Hemost 32:90-7. 2006
  5. doi request reprint Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children
    Chantal Loirat
    Service de Nephrologie, Hopital Robert Debre, Assistance Publique Hopitaux de Paris, Universite Paris VII, 48 Boulevard Serurier, 75019, Paris, France
    Pediatr Nephrol 24:19-29. 2009
  6. pmc Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience
    Paul Coppo
    Service d Hématologie et de Thérapie Cellulaire, AP HP, Hopital Saint Antoine, Paris, France
    PLoS ONE 5:e10208. 2010
  7. doi request reprint Human immunodeficiency virus-associated thrombotic microangiopathies: clinical characteristics and outcome according to ADAMTS13 activity
    S Malak
    Service d Hématologie et de Thérapie Cellulaire, AP HP, Hôpital Saint Antoine and UPMC Université Paris 06, Paris, France
    Scand J Immunol 68:337-44. 2008

Collaborators

Detail Information

Publications7

  1. doi request reprint [ADAMTS13, von Willebrand factor specific cleaving protease]
    Agnes Veyradier
    Service d Hematologie Biologique, Hopital Antoine Beclere, Groupe Hospitalier Paris Sud, AP HP, 157, rue de la Porte de Trivaux, 92140 Clamart, France
    Med Sci (Paris) 27:1097-105. 2011
    ..A better characterization of ADAMTS13 structure/function combined to clinical trials led in TTP patients is crucial to evaluate the relevance of either a -plasma-purified or a -recombinant ADAMTS13 as a therapeutic agent...
  2. doi request reprint Validation of the first commercial ELISA for type 2N von Willebrand's disease diagnosis
    A Veyradier
    Service d Hematologie Biologique, Hopital Antoine Beclere, Clamart Cedex, France
    Haemophilia 17:944-51. 2011
    ..In conclusion, the Asserachrom® VWF:FVIIIB is easy to perform, standardized and accurate for type 2N VWD diagnosis with a 100% sensitivity and specificity...
  3. doi request reprint Von Willebrand factor and ADAMTS13: a candidate couple for preeclampsia pathophysiology
    Alain Stepanian
    AP HP Hôpital Antoine Béclère, Service d Hematologie Biologique, 157 rue de la Porte de Trivaux, 92141 Clamart Cedex, France
    Arterioscler Thromb Vasc Biol 31:1703-9. 2011
    ....
  4. ncbi request reprint Thrombotic thrombocytopenic purpura associated with von Willebrand factor-cleaving protease (ADAMTS13) deficiency in children
    Chantal Loirat
    Service de Nephrologie Pediatrique, Hopital Robert Debre, Paris, France
    Semin Thromb Hemost 32:90-7. 2006
    ..FFP infusions are best used preventively, given that rescue infusions may not prevent central nervous system and renal involvement. It is hoped that plasmatic or recombinant purified ADAMTS13 will be available in the years to come...
  5. doi request reprint Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children
    Chantal Loirat
    Service de Nephrologie, Hopital Robert Debre, Assistance Publique Hopitaux de Paris, Universite Paris VII, 48 Boulevard Serurier, 75019, Paris, France
    Pediatr Nephrol 24:19-29. 2009
    ..Therapeutic perspectives are focused on the development of concentrated plasma-derived ADAMTS13 or recombinant ADAMTS13...
  6. pmc Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience
    Paul Coppo
    Service d Hématologie et de Thérapie Cellulaire, AP HP, Hopital Saint Antoine, Paris, France
    PLoS ONE 5:e10208. 2010
    ..3%, sensitivity of 98.8%, and specificity of 48.1%. Our criteria should be useful to identify rapidly newly diagnosed patients with an acquired ADAMTS13 deficiency to better tailor treatment for different pathophysiological groups...
  7. doi request reprint Human immunodeficiency virus-associated thrombotic microangiopathies: clinical characteristics and outcome according to ADAMTS13 activity
    S Malak
    Service d Hématologie et de Thérapie Cellulaire, AP HP, Hôpital Saint Antoine and UPMC Université Paris 06, Paris, France
    Scand J Immunol 68:337-44. 2008
    ..04). In conclusion, HIV-associated TMA with severe ADAMTS13 deficiency have less AIDS-related complications and a higher CD4(+) T cell count. TMA prognosis is better and comparable to this of idiopathic forms...